On the other hand, although pemafibrate is a new TG-lowering agent, single-arm preliminary studies conducted in Japan showed that pemafibrate decreased levels of ALT, γ-GTP and ALP and improved surrogate markers for liver fibrosis and cirrhosis (32–36). This evidence concerns the gene GPT and Hepatic fibrosis.